

An Asthma Update for Nurses

Montana Nurses Association October 6, 2022

Cyndi Leaphart, RN


Overview of Today's Presentation



- 1. Brief review of pathophysiology
- 2. Asthma Guidelines update
 - a) Assigning severity rating
 - b) Using stepwise therapy to select asthma medications
 - c) Transitioning patients to smart therapy
 - d) Monitoring asthma control
 - e) Using AAP to education pt. on treatment plan
- 3. Asthma clinic visits and the nurse's role ACT



Four Components of Asthma Management



Assessment and Monitoring

Control of Factors Contributing to Asthma Severity

 Education for a Partnership in Asthma Care

Pharmacological Therapy



Asthma is.....

1. Chronic inflammatory disorder of the airways

- Mast cells, eosinophils and lymphocytes infiltrate into airway lining
- Airway hyper-responsiveness

2. Excessive reaction to "minor" irritants results in:

- Bronchial wall edema
- Smooth muscle contraction

3. Excess mucus production




What is Asthma?





Pathophysiology of asthma






Asthma Medications

Quick relief medications

- Used to treat or relieve asthma symptoms & prevent EIA
- Should ALways have it with them (ALbuterol)
- Opens airways by relaxing the muscles that surround the airway to provide prompt relief of symptoms
- Works very quickly, but for a short period of time (3-4 hrs)
- Will not provide long term asthma control
- Examples: Albuterol, ProAir, Proventil, Ventolin, Xopenex

Long term control medications

- Use daily to prevent symptoms, often by reducing inflammation
- With reduced inflammation on the inside of the airway and helps to prevent future episodes
- Must be taken daily
- Will not give quick relief
- Examples: Flovent, Pulmicort, Qvar, Asmanex, Advair, Dulera, Symbicort






Why do people get asthma

Experts are still unsure of the exact causes of asthma

Factors may include:

- Environment
- Genetics
- Obesity
- Exposure to childhood diseases
- Inactivity
- Smoking during pregnancy
- · Secondhand smoke

Behavior





Health Disparities Related to Asthma in Montana

Total Asthma Prevalence in Montana: 10% of all adults – over 100,000

Asthma Prevalence in Children in Montana: 6.7% - approximately 15,000

Gender: Females higher rate than Males


Race: American Indians/Alaskan Natives higher rate than White, Non Hispanic

Median Household income: Lower household income = Higher asthma prevalence

Overweight/Obese: Higher BMI = Higher risk of developing asthma

Smoking: Tobacco is a common trigger and can increase symptoms

Figure 2. Percent of Adults with Current Asthma by Sex, Age, and Race, Montana, BRFSS, 2015-2019





Guidelines Implementation Panel: Priority Messages

Assess asthma severity Assess and monitor asthma control

Use inhaled corticosteroids

Use written asthma action plans

Schedule follow-up visits

Control environmental exposures



Distinguishing between Severity and Control?

Severity: the intrinsic intensity of the disease process

Assess to initiate therapy

- Intermittent/Persistent
- Mild Persistent
- Moderate Persistent
- Severe Persistent

Control: the degree to which symptoms are minimized by therapeutic interventions

- Monitor to adjust therapy
- Well controlled
- Not well controlled
- Very poorly controlled





Asthma Severity Is the Cornerstone of Therapy



Physicians underestimate the severity of asthma classification

Braganza, S. 2005. J of Asthma. https://doi.org/10.1081/JAS-120019037

Only of 40% of pediatric asthma patients had asthma severity ratings

Arch Pediatr Adolesc Med. 2002;156(2):141-146. doi:10.1001/archpedi.156.2.141

Inaccurate severity rating leads to suboptimal therapy

Less use of ICS; more exacerbations

Black patients are more likely than white patients to have severity underestimated. (Okelo, S. 2007. J General Inter Med. 22).



Decision Support Tools Can Help



- Daytime symptoms
- 2. Nighttime symptoms
- SABA use
- Interference with daily activities
- Lung function



		Intermittent		Persistent								
components of		Intermittent			Mild			Moderate			Severe	
Seventy	Ages Ages Ages 0-4 years 5-11 years 212 years		Ages 0-4 years	Ages S-11 years	Ages in12 years	Ages 0-4 years	Ages S-11 years	Ages in12 years	Ages 0-4 years	Ages S-11 years	Ages in12 years	
Symptoms		≼2 days/week		>2 days/week but not daily Daily Throu				roughout the day				
Nighttime awakenings	0 «Zx/month		nonth	1-2x/month 3-4x/month		3-4x/month >5x/week but not nightly		Hx/week Often 7x/wee		x/week		
SABA* use for symptom control (not to prevent EIB*)	≼2 days/week			>2 days/week but not daily and not more than once on any day		Daily		Several times per day				
Interference with normal activity	None			,	Minor limitation	K.		Some limitation Extremely limited			d	
Lung function FEV,*(% predicted)	Not applicable	Normal FEV, between exace/bations >80%	Normal FEV, between exacerbations >80%	Not applicable	HBO%	>80%	Not applicable	60-80%	60-80%	Not applicable	460%	×80%
◆ FEV/FVC*		>05%	Normal ¹		>00%	Normal ¹		75-80%	Reduced \$%*		<75%	Reduced >5% ¹
Asthma exacerbations				or wheezing			nd intense events indicate greater seventy.			\Rightarrow		
requiring oral systemic corticosteroids ¹		O-Vyear		year lasting >1 day AND risk factors for persistent asthma	>2/5	year	Generally, more	frequent and i	ntense events inc	dcate greater sa	nventy:	
	Consider sevenity and interval since last asthma exacerbation. Frequency and sevenity may fluctuate over time for patients in any sevenity category. Relative annual risk of exacerbations may be related to FEV,*											
rmended Step for ing Therapy							Dan I	Step 3	Sten 1	Sten I	Step 3 medium-dose	
tepwise Approach for ing Asthma Long Term,")	Step 1		Step 2		ICS* option		ICS* option or Step 4		or 5			
pwise approach is meant not replace, the clinical											ticosteroids	
	Nighttime awakenings SABA* use for symptom control (not to prevent EID*) interference with normal activity Lung function FEV,* (% predicted) FEV,FVC* Asthma exacerbations requiring oral systemic conticusteroids* mended Step for ag Therapy repwise Approach for ag Asthma Long Term,* twise approach is meant	Symptoms Nighttime awakenings SABA* use for symptom control (not to prevent EIB*) Interference with normal activity Lung function FEV,* (% predicted) FEV/FVC* Asthroa exacerbations requiring oral systemic corticosteroids* mended Step for ag Therapy repwise Approach for ag Asthroa Long Term,* owise approach it meant not replace, the clinical*	Symptoms Symptoms Ages S-11 years 2 days/week SABA* use for symptom control (not to prevent EIB*) Interference with normal activity Lung function FEV,* (% predicted) FEV,* (% predicted) FEV,* (% predicted) FEV,* (% predicted) Asthma exacerbations requiring oral systemic conticosteroids Consider se mended Step for rig Therapy spewise Approach for rig Asthma Long Term,* wellse approach is meant not replace, the clinical covies approach is meant not replace, the clinical	Symptoms Nighttime awakenings SABA* use for symptom control (not to prevent EIB*) Interference with normal activity Lung function FEV,* (% predicted) FEV/FVC* Authma exacerbations requiring onal systemic contricosteroids* Consider seventy and interference or to prevent exacerbations Consider seventy and interference or to prevent exacerbations SABA* use for symptom control (not to prevent EIB*) None None Normal FEV, between exacerbations exacerbations exacerbations or FEV/FVC* Authma exacerbations requiring onal systemic contricosteroids* Consider seventy and interference or to prevent exacerbations in the clinical or replace, the clinical or replace or replace to the clinical or replace to the clin	Ages O-4 years O-4 years Symptoms 2 days/week S-2 days/week	Ages Ages Ages Ages Ages Ages Ages Ages S-11 years	Ages 0-4 years S-II years 12 years 12 years S-II years 2 days/week but not daily Nighttime awakenings 0	Ages O-4 years S-11 years 2d days/week but not daily Nighttime awakenings 0 42k/month 1-2k/month 3-4k/month 3	Ages O-4 years S-11 years Ages S-11 years S-12 years S-	Ages 0-6 years 5-11 years 2-12 years 5-11 years 3-12 ye	Ages O-4 years S-11 years at 23 years O-4 years S-11 years O-4 years S-12 years O-4 years O-	Severity Ages O-4 years S-11 years Ages O-2 years S-11 years Ages O-3 years S-11 years

Classification of Asthma Severity Components of (Youths ≥12 years of age and adults) Severity Persistent Intermittent Mild **Moderate** Severe ≤2 days/week >2 days/week Daily Throughout Symptoms but not daily the day ≤2x/month 3-4x/month >1x/week but Often 7x/week Nighttime not nightly awakenings ≤2 days/week Short-acting >2 days/week Daily Several times per day but not beta₂-agonist use >1x/day **Impairment** for symptom control (not prevention of EIB) Normal FEV, /FVC: 85% Minor limitation Some limitation Extremely limited 8-19 vr None Interference with 20 -39 vr 80% normal activity 40 -59 vr 75% 60 -80 yr 70% Normal FEV₁ between exacerbations • FEV, >80% FEV₁ ≥80% • FEV, >60% but • FEV, <60% Lung function predicted <80% predicted predicted predicted • FEV₁/FVC · FEV,/FVC • FEV₁/FVC • FEV₁/FVC reduced 5% reduced >5% normal normal 0-1/year ≥2/year (see note) -(see note) Exacerbations requiring oral Consider severity and interval since last exacerbation. Frequency and ___ Risk severity may fluctuate over time for patients in any severity category. systemic corticosteroids Relative annual risk of exacerbations may be related to FEV₁

American Lung Association.

Components of				f Asthma S s of age an	the state of the s			
Sev	erity							
			Mild	Moderate	Severe			
	Symptoms	≤2 days/week	>2 days/week but not daily	Daily	Throughout the day			
Impairment Normal FEV ₁ /FVC: 8–19 yr 85% 20 –39 yr 80% 40 –59 yr 75%	Nighttime awakenings	≤2x/month	3-4x/month	1x/week but not nightly	Often 7x/week			
	Short-acting beta ₂ -agonist use for symptom control (not prevention of EIB)	≤2 days/week	>2 days/week but not >1x/day	Daily	Several times per day			
	Interference with normal activity	None	Minor limitation	Some limitation	Extremely limited			
50 –80 yr 70%	Lung function	Normal FEV ₁ between exacerbations FEV ₁ >80% predicted FEV ₁ /FVC normal	• FEV ₁ ≥80% predicted • FEV ₃ /FVC normal	FEV ₁ > 60% but < 80% predicted FEV ₁ /FVC reduced 5%	FEV, <60% predicted FEV,/FVC reduced >5%			
	Exacerbations	0-1/year (see note) ≥2/year (see note)						
Risk	requiring oral systemic	Consider severity and interval since last exacerbation. Frequency and severity may fluctuate over time for patients in any severity category.						
	corticosteroids	Relative	annual risk of exac	erbations may be rela	ted to FEV ₁			



INITIAL VISIT: CLASSIFYING ASTHMA SEVERITY AND INITIATING THERAPY

(in patients who are not currently taking long-term control medications)

Level of severity (Columns 2-5) is determined by events listed in Column 1 for both impairment (frequency and intensity of symptoms and functional limitations) and risk (of exacerbations). Assess impairment by patient's or caregiver's recall of events during the previous 2-4 weeks; assess risk over the last. Recommendations for initiating therap based on level of severity are presented in the last row.

			Intermittent						Persistent					
	Components of Severity	Ages Ages Ages 0-4 years 5-11 years 212 years		Mild			Moderate			Severe				
	Seventy			O-4 years	Ages S-II years	Ages 212 years	Ages 0-4 years	Ages S-II years	Ages 212 years	O-4 years	Ages S-II years	Ages 212 years		
	Symptoms		s2 days/week		>2 day	rs/week but no	ot disily		Delity		7	hroughout the o	Say	
	Nighttime awakenings	0 s2x/month s2 days/week		1-2x/month 3-4x/month		3-4x/month >tx/week but not nightly		>ts/week Often 7s/week		7x/week				
·	SABA" use for symptom control (not to prevent ERS")			>2 days/week but not daily and not more than once on any day		Delly			Several times per day					
ě	Interference with normal activity		None		,	Hinor limitation			Some limitation	м.		Extremely limits	nd	
STATE OF THE STATE	Lung function FEV,* (% predicted) FEV/FVC*	Not applicable	Normal FEV, between executations HEON	Normal FEV, between executations >80% Normal*	Not applicable	>80% >80%	>80% Normal*	Not applicable	60-80% 75-80%	60-80% Reduced 1%*	Nest applicable	<60% <75%	<60% Reduced +9	
T					a2 exacerb. in 6 months.	Control		-		ter en entre		-		
	Asthma exacerbations				or wheeling	wheezing		and intense events indicate greater sevenity						
	requiring and systemic corticosteroids ²		O-Myear		year lasting	year lasting x2/year		year I	Generally, more frequent and intense events in			edicate greater seventy.		
MA					AND raik factors for persistent authors	NO risk ctors for projected						,		
			Consider as	evenity and inter	vel since last ast			and sevenity m adions may be i			nits in any sever	ity category:		
Imittie	ommended Step for sting Therapy "Stepwise Approach for		for I					Step 3	Step 1 medium-dose	Step 3	Step 3	Step 3 medium-dose ICS* option	Step 4 or 5	
	aging Authma Long Term,"	Step 1		Step 2			ICS* option			or Step 4				
The x	deposite approach is meant do, not replace, the clinical				Consider short course of oral systemic cortico				rticosferoids.					
decis	spring readed to meet straig patient reads.				weeks, depending of years old, if n									



Intermittent Asthma

Persistent Asthma: Daily Medication

Consult with asthma specialist if step 4 care or higher is required. Consider consultation at step 3.



Step up if needed

(first, check adherence, environmental control, and comorbid conditions)

> ASSESS control

Step down if

possible (and asthma is well controlled at least 3 months)



Step 3

Step 2

Preferred:

Low-dose ICS

Alternative:

Cromolyn, LTRA,

Nedocromil, or

Theophylline

Preferred:

Low-dose ICS + LABA OR

Medium-dose ICS

Alternative: Low-dose ICS + either LTRA. Theophylline, or Zileuton

Step 4

Preferred:

Medium-dose ICS + LABA

Alternative:

Medium-dose ICS + either LTRA. Theophylline, or Zileuton

Step 5

Preferred:

High-dose ICS + LABA

AND

Consider Omalizumab for patients who have allergies

Step 6

Preferred:

High-dose ICS + LABA + oral corticosteroid

AND

Consider Omalizumab for patients who have allergies

Step 1

Preferred:

SABA PRN

Each step: Patient education, environmental control, and management of comorbidities.

Steps 2-4: Consider subcutaneous allergen immunotherapy for patients who have allergic asthma (see notes).

Quick-Relief Medication for All Patients

- SABA as needed for symptoms. Intensity of treatment depends on severity of symptoms: up to 3 treatments at 20-minute intervals. as needed. Short course of oral systemic corticosteroids may be needed.
- Use of SABA >2 days a week for symptom relief (not prevention of EIB) generally indicates inadequate control and the need to step. up treatment.

Key: Alphabetical order is used when more than one treatment option is listed within either preferred or alternative therapy. EIB, exercise-induced bronchospasm; ICS, inhaled corticosteroid; LABA, long-acting inhaled betagagonist: LTRA, leukotriene receptor antagonist: SABA, inhaled short-acting betay-agonist

ESTIMATED COMPARATIVE DAILY DOSAGES: INHALED CORTICOSTEROIDS FOR LONG-TERM ASTHMA CONTROL

		-4 years of age			5-11 years of age		≥12 years of age			
Daily Dose	Low	Medium*	High:	Low	Medium*	High*	Low	Medium*	High:	
MEDICATION										
Beclomethasone MDI'	N/A	N/A	N/A	80-160 mcg	>160-320 mcg	>320 mcg	80-240 mcg	>240-480 mcg	>480 mcg	
40 mcg/puff				1-2 puffs 2x/day	3-4 puffs 2x/day		1-3 puffs 2x/day	4-6 puffs 2x/day		
80 mcg/puff				1 puff 2x/day	2 puffs 2x/day	a3 puffs 2x/day	1 puff am, 2 puffs pm	2-3 puffs 2x/day	a4 puffs 2x/day	
Budesonide DPI*	N/A	N/A	N/A	180-360 mcg	>360-720 mcg	>720 mcg	180-540 mcg	>540-1,080 mcg	>1,080 mcg	
90 mcg/inhalation	1			1-2 inhs' 2x/day	3-4 inhs' 2x/day		1-3 inhs' 2x/day			
180 mcg/ inhalation					2 inhs* 2x/day	a3 inhs* 2x/day	1 inh' am, 2 inhs' pm	2-3 inhs' 2x/day	a4 inhs* 2x/day	
Budesonide Nebules	0.25-0.5 mg	>0.5-1.0 mg	>1.0 mg	0.5 mg	1.0 mg	2.0 mg	N/A	N/A	N/A	
0.25 mg	1-2 nebs*/day			1 neb* 2x/day						
0.5 mg	1 neb*/day	2 nebs*/day	3 nebs'/day	1 neb*/day	1 neb* 2x/day					
1.0 mg		1 neb*/day	2 nebs*/day		1 neb*/day	1 neb1 2x/day				
Ciclesonide MDI	N/A	N/A	N/A	80-160 mcg	>160-320 mcg	>320 mcg	160-320 mcg	>320-640 mcg	>640 mcg	
80 mcg/puff				1-2 puffs/day	1 puff am. 2 puffs pm- 2 puffs 2x/day	a3 putts 2x/day	1-2 puffs 2x/day	3-4 puffs 2x/day		
160 mcg/puff				1 puff/day	1 puff 2x/day	a2 puffs 2x/day		2 puffs 2x/day	≥3 puffs 2x/day	
Flunisolide MDI	N/A	N/A	N/A	160 mcg	320-480 mcg	a480 mcg	320 mcg	>320-640 mcg	>640 mcg	
80 mcg/puff	1			1 puff 2x/day	2-3 puffs 2x/day	a-4 puffs 2x/day	2 puffs 2x/day	3-4 puffs 2x/day	a5 puffs 2x/day	

^{*} It is preferable to use a higher mog/puff or mog/inhalation formulation to achieve as low a number of puffs or inhalations as possible.



^{*} Abbreviations: DPI, dry powder inhaler (requires deep, fast inhalation); inh, inhalation; HDI, metered dose inhaler (releases a puff of medication); neb, nebule.

AGES 5-11 YEARS: STEPWISE APPROACH FOR MANAGEMENT OF ASTHMA

	Intermittent Asthma	Manag	ement of Persiste	ent Asthma in Ind	ividuals Ages 5-	I1 Years	
Treatment	STEP 1	STEP 2	STEP 3	STEP 4	STEP 5	STEP 6	
Preferred	PRN SABA	Daily low-dose ICS and PRN SABA	Daily and PRN combination low-dose ICS-formoterol •	Daily and PRN combination medium-dose ICS-formoterol	Daily high-dose ICS-LABA and PRN SABA	Daily high-dose ICS-LABA + oral systemic corticosteroid and PRN SABA	
Alternative		Daily LTRA,* or Cromolyn,* or Nedocromil,* or Theophylline,* and PRN SABA	Daily medium- dose ICS and PRN SABA or Daily low-dose ICS-LABA, or daily low-dose ICS + LTRA,* or daily low-dose ICS +Theophylline,* and PRN SABA	Daily medium- dose ICS-LABA and PRN SABA or Daily medium- dose ICS + LTRA* or daily medium- dose ICS + Theophylline,* and PRN SABA	Daily high-dose CS + LTRA* or daily high-dose CS + Theophylline,* and PRN SABA	Daily high-dose ICS + LTRA* + oral systemic corticosteroid or daily high-dose ICS + Theophylline* + oral systemic corticosteroid, and PRN SABA	
		immunotherapy as an in individuals ≥ 5 years	lly recommend the use of adjunct treatment to star of age whose asthma is d maintenance phases of	ndard pharmacotherapy controlled at the	Consider Omalizumab**▲		

Note Steps 2-4: Conditionally recommend the use of subcutaneous immunotherapy as an adjunct treatment in ≥5 years of age. If Step 4 or higher is needed, consider asthma specialist.



SMART Therapy (Single Maintenance and Reliever Therapy)

Not new concept (Scicchitano 2004, Rabe 2006, Chapman 2010) SMART is for Step 3 (low-dose ICS) and Step 4 (medium-dose ICS).

For individuals whose asthma is uncontrolled on ICS-LABA with SABA as quick-relief.

SMART used for controller therapy AND quick-relief therapy.

Patients with exacerbations in prior year are good candidates

Considerations: Lower risk of growth suppression, 1 month supply may not be sufficient for both controller and quick- relief; spacer recommended.

Meta-analysis of 16 randomly controlled trials with 22,748 patients. For patients >12 years, SMART was associated with reduced exacerbations compared to ICS at same dose or ICS-LABA at higher dose as controller therapy. (Sobieraj, D, 2018, JAMA).



Current SMART Therapy Options

Symbicort MDI (budesonide/formoterol)

6-11 yo: 80/4.5 2 puffs 2x/day

≥12 yo: 80-160/4.5 2 puffs 2x/day

Spacer recommended

Max doses/day: 8 for children; 12 for adults

Dulera MDI (mometasone/ formoterol)

5-11 yo: 50/5 2 puffs 2x/day

>12 yo: 100-200/5 2 puffs

2x/day

Spacer recommended

Max doses/day: 8 for kids; 12 for adults

Symbicort DPI*: Ages ≥ 12: Dose 200/6 mcg 1 to 2 puffs twice daily; May increase to 4 puffs twice daily If ≥ 18 yo Max: 6 inhalations at a single time, no more than 12 inhalations daily

Symbicort DPI*: Ages 6-11 Dose 100/6 mcg 1 inhalation twice daily

Symbicort DPI*: Ages 6-11 Dose 100/6 mcg 1 inhalation twice daily

*Not currently available in the United States

SMART Therapy (Single Maintenance and Reliever Therapy)

- Inhaled ICS-formoterol in a single inhaler used for controller and reliver
- SMART is appropriate for Step 3 (low-dose ICS) and Step 4 (medium-dose ICS)
- ICS-formoterol should be administered as
 - Maintenance therapy with 1-2 puffs once or twice daily (depending on age, asthma severity and ICS dose)
 - And 1-2 puffs as needed for asthma symptoms
- Benefits
 - Lower risk of growth suppression
 - 1 month supply may not be sufficient for both write on prescription
 - Spacer recommended
 - Patients with exacerbations in the prior year are good candidates
- FDA approval for these drugs are at age 5 but the new guidelines recommend using it starting at age 4 so technically, this is an off-label use

SABA overuse leads to exacerbations, ED visits, hospitalizations, death

Overuse is a big problem


High SABA usage indicates poor control and a need to reassess controller medications/adherence and triggers.

Should be prescribed 1 or 2 at a time (not 11 refills).




Why use a spacer with a multi dose inhaler?

Why use a Spacer with an Inhaler?



Inhaler alone

When an inhaler is used alone, medicine ends up in the mouth, throat, stomach and lungs.



Inhaler used with spacer device

When an inhaler is used with a spacer device, more medicine is delivered to the lungs.

erican
____ng
Association.









Collapsible spacers





What is an Asthma Action Plan and do I really need it?



- Created in partnership with the patient for guided self-management
- Addresses daily management to maintain control
- Identifies what to do by recognizing and handling worsening asthma



Created in Partnership with the Patient

Is AAP understandable and culturally appropriate?

FORMAT

- Can range from simple design to more detailed design
- Age appropriate, child/adult versions
- Increased font size for elderly
- Includes visual elements

LANGUAGE

- Use language that is understandable to the patient (i.e., Advair, "flat, purple inhaler"; Proventil, "yellow pump")
- Use culturally appropriate imagery

Tailor the plan to the patient

ACCESSIBILITY

SYMPTOM-BASED VS. PFM-BASED

- Symptoms only
- Symptoms plus peak flow

- Consider who should have a copy, such as parents, caregivers, teachers, coaches, and other childcare providers
- Available in print format, triplicate form, webbased, or mobile-friendly



Health Literacy and the AAP

Self-management skills poorer among patients with limited reading ability. 1 out of 4 cannot understand basic written material (Kirsh, 1993).

AAPs should meet readability standards of fifth grade level or lower.



American Lung Association	Mv As	cthma Action	
•		istent	
, ,		Can work and play – Sleeps we 80% of personal best)	ell at night
Flu Vaccine—Date receiv Control Medicine(s)	ved: Next flu vaccine Medicine	e due: COVID19 vac How much to take	
Physical Activity	☐ Use Albuterol/Levalbute☐ with all activity ☐ whe	erol puffs, 15 minutes b en you feel you need it	efore activity
Yellow Zone: Caution			
		or tight chest - Problems work tween 50% and 79% of persona	
Quick-relief Medicine(s) Control Medicine(s)	Continue Green Zone m	nedicines	
		ick-relief treatment. If you an instructions in the RED ZONE	e getting worse or are in the and call the doctor right away!
Red Zone: Get Help No	ow!		
	ems breathing - Cannot work of Meter (less than 5	, ,	f better - Medicine is not helping
	_ ,	. Line or fineerneile	alking due to shortness of breath

Emergency Contact Name ___

• Still in the Red Zone after 15 minutes




Plan de acción contra el asma para el hogar y la escuela

Nombre: Fecha de nacimiento:// Clasificación de gravedad:
Zona verde: Anda bien
Sintomas: La respiración es buena – Sin tos ni resuello – Puede trabajar y jugar – Duerme bien a la noche Flujómetro (más del 80% de la mejor marca personal)
Vacuna contra la gripe - Fecha de aplicación: Fecha de próxima vacuna contra la gripe: Vacuna contra la COVID-19 - Fecha de aplicación: Medicamento/s Medicamento Cuánto tomar Cuándo y con qué frecuencia tomario de control
Actividad física usa albuterol/levalbuterol puffs, 15 minutos antes de la actividad con todas las actividades usando el niño siente que lo necesita
Zona amarilla: Precaución
Sintomas: Algunos problemas de respiración – Tos, resuello, u opresión en el pecho – Problemas para trabajar o jugar – Se despierta a la noche Flujómetro a
Medicamento/s de alivio rápido Medicamento/s de control Albuterol/levalbuterol Inhalciones cada 20 minutos por hasta 4 horas segun sea necesario Medicamento/s de control Continuar con los medicamentos de la Zona verde Agregar Cambiar por
El niño se debe sentir mejor dentro de 20-60 minutos del tratamiento de alivio rápido. Si el niño empeora o está en la Zona amarilla durante más de 24 horas, siga las instrucciones de la ZONA ROJA y llame al médico inmediatamente.
Zona roja: iConsigue ayuda ahora!
Síntomas: Muchos problemas de respiración – No puede trabajar o jugar – Empeora en vez de mejorar – El medicamento no ayuda Flujómetro (menos del 50% de la mejor marca personal)
iTome el medicamento de alivio rápido AHORA! ☐ Albuterol/levalbuterol ☐ puffs, ☐ (con qué frecuencia) Llame al 911 inmediatamente si presenta las siguientes señales de peligro • Dificultad para caminar/hablar debido a la falta de aire • Lablos o uñas azules • Sigue en la zona roja después de 15 minutos
ersonal escolar: Siga las instrucciones de la Zona amarilla y roja respecto de los medicamentos de alivio rápido de acuerdo con los sintomas el asma. Los únicos medicamentos de control que podrán administrarse en la escuela son los que figuran en la Zona verde con una tilde junto a fomar en la escuela".
su inhalador de alivio rápido, incluida la capacidad de avisar a un adulto si los síntomas no mejoran después de tomar el medicamento.
Proveedor de atención médica Nombre Fecha Teléfono () Firma
Padre/futor Autorizo que un enfermero u otro personal escolar administren en la escuela los medicamentos que figuran en el plan de acción según corresponda. Autorizo la comunicación entre la clinica o el proveedor de atención médica que prescribe, el enfermero de la escuela, el asesor médico de la escuela y los proveedores de la clinica de salud ubicada en la escuela que sea necesaria para el contol del asma y la administración de este medicamento. Nombre
Enfermero de la escuela El estudiante ha demostrado capacidad para llevar y auto-administrarse su inhalador de alivio rápido, incluida la capacidad de avisar a un adulto si los sintomas no mejoran después de tomar el medicamento.
Nombre Fecha Tellifono () Firma
Envie una copia firmada al proveedor que figura arriba. 1-800-LUNGUSA Lung.org


American Lung Association.

ALA Asthma AP Spanish Home_School V1 2 16 2022

Find a plan appropriate for YOUR patient



Please review the Action Plan with your practitioner twice a year, within 3 months of a medication change or within 3 weeks following on emergency deportment or hospital war, For Healthgris IC, Stol 8-1-1.





Find a plan appropriate for YOUR patient



Child is Well

...and has no asthma symptoms, even during play



Child is Not Well

...and has asthma symptoms that may include:

- Coughing
- Wheezing
- · Runny nose or other cold symptoms
- Breathing harder or faster
- Waking due to coughing or difficulty breathing
- · Playing less than usual

Other symptoms that could indicate that your child is having difficulty breathing may include: difficulty feeding (grunting sounds, poor sucking), changes in sleep patterns, cranky and tired, decreased appetite



Child Feels Awful!

Warning signs may include:

- Child's wheeze, cough or difficulty breathing continues or worsens, even after giving Yellow Zone medications
- Child's breathing is so hard that he/she is having trouble walking/talking/ eating/playing or child is drowsy or less alert than normal





led Zone

Using a spacer

How to care for your spacer

Asthma +Respiratory FOUNDATION NZ

Child Asthma

Action Plan

If you use a metered dose inhaler (MDI), a spacer will help to get the right dose of medicine into your lungs. Your doctor can give you a spacer for free. Remember not to share your spacer with anyone else, and ask for a new one every year.



1 Hold the inhaler upright and give it a good shake



Fit the inhaler into the opening at the end of the spacer



Seal the lips firmly around the mouth piece - press the inhaler ance only



Take 6 slow breaths in and out through your mouth. Do not remove the spacer from your mouth between breaths



Remove the spacer from your mouth, Repeat steps 1-4 for further doses



Take the spacer apart (both the small and the larger spacer dismantle into 2 pieces)



Use warm water with a little dishwashing liquid and hand wash your spacer



Do not rinse or wipe the spacer. Leave the pieces on the side to dry



Put the spacer back together



Produced by the Asthma and Respiratory Foundation NZ

- 04 499 4592 n 04 499 4594
- nfo@asthmaanutespiratory.org.nz @ asthmaandrespiratory.org.nz Updawd Aug 2017- ASTH10

Mame:

Better breathing, better living



Well

When I'm well:

- I have no cough
- I play just like other children
- I use my reliever puffer less than 2 times a week

My puffers are:

Preventer: I take this every day even when I'm well.

The name of my preventer is The colour is puffs in the morning and puffs at night through a spacer.

Reliever: I take this only when I need it

The name of my reliever is The colour is

puffs through a spacer when I wheeze, cough or when it's hard to breathe.

If I find it hard to breathe when I exercise I should: Take puffs of my reliever



Worse

When my asthma is getting worse:

- I cough or wheeze and it's hard to breathe, or
- I'm waking at night because of my asthma, or
- I cough or wheeze when I play, or I need my reliever inhaler to control my
- asthma more than 2 times per week

if my asthma gets worse I should:

Keep taking my preventer every day as normal and take puffs of my reliever every 4 hours If I'm not getting better doing this I should see my doctor today

Contact:



Worried

My asthma is a worry when:

- My reliever isn't helping, or
- I'm finding it hard to breathe, or
- I'm breathing hard and fast, or
- I'm sucking in around my ribs/throat, try looking under my shirt
- I'm looking pale or blue

- Sit me down and try to stay calm
- Give me 6 puffs of reliever through a spacer, taking 6 breaths for each puff
- If I don't start to improve I need help now

Emergency

DIAL 111 and ask for an ambulance WHILE YOU'RE WAITING:

- Try to stay calm and keep me sitting upright
- Give 6 puffs of reliever through a spacer every 5 minutes with 6 breaths for each puff until help arrives

Date Prepared: Doctors Signature: Plan to be reviewed when treatment changed

The NAAP Instrument

Navajo Asthma Action Plan












Asthma Action Plans



- Written instructions
- Zones:
 - Daily Management–green zone
 - All controller meds
 - Recognizing and handling worsening asthma:
 - Yellow zone
 - Red zone





Patient is doing well
No symptoms
Control medications listed here
Do not put "albuterol PRN" – give specific guidelines
EIA – pre-exercise albuterol in Physical activity section



Red Zone: Get Help Now!

Symptoms: Lots of problems breathing - Cannot work or play - Getting worse instead of better - Medicine is not helping Peak Flow Meter _____ (less than 50% of personal best)

Take Quick-relief Medicine NOW! Albuterol/Levalbuterol _____ puffs, _____ (how frequently)

Call 911 immediately if the following danger signs are present: • Trouble walking/talking due to shortness of breath

- Lips or fingernails are blue
- Still in the Red Zone after 15 minutes.



Worsening symptoms Quick relief medications – name, dosage and when to take When to call 911





Patient does not feel well but not emergent, chest tightness, cough, tiring out sooner than normal


Use spacer with MDI – write that on AAP

Guidelines state 4-8 puffs q 20 min x 4 hrs

Call provider if not better in 24 hrs

Many have gradual recovery and inflammation may continue for 2-3 weeks

Revising Asthma Action Plans



- Control—adjust until optimal
- Ongoing assessment and communication
- Trial and error, always subject to revision
- Reassess at every visit



Suggestions for Pre-Visit Planning Process



- 1. ED/Hospitalization follow-up documentation
- 2. ACT
- 3. Spirometry test
- 4. Medication reconciliation
- 5. Asthma Action Plan
- 6. Known allergies/triggers
- 7. Vaccines
- 8. Placebo medical delivery device for teaching purposes
- 9. Written or demonstration education materials



Questions to ask patient while checking in for an asthma visit

- Continue to establish rapport with patient using simple language
- Review jointly developed treatment goals at every visit
- Ask relevant questions
 - What worries you most about your asthma? What do you want to accomplish today?
 - What do you want to be able to do that you can't now because of asthma?
 - Can you afford your meds and get to the pharmacy to pick them up?
 - Are there things in your environment that trigger you? How do you handle that?
 - What other questions do you have for me or your provider today?
- Emphasize self management at every visit
- Review meds at every visit
- Make f/u appointment and review AAP before discharge from office ensure patient knows what s/s indicates worsening condition – phone number for office contact



Asthma Self-Assessment: Why?

Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma, 2007

1. Select treatment based on a patient's individual needs and level of asthma control.

2. While asthma can be controlled, the condition can change over time and differs among individuals and by age groups.



Validated Patient Self-Assessment Options

- 1. ACT Asthma Control Test (GSK)
- 2. ATAQ (20 item questionnaire)
- 3. ACQ (7 item questionnaire)
- 4. TRACK (AZ and American Academy of Peds)
- 5. AirQScore.com (AZ)



Asthma Control Test (ACT)

- Gives a numerical score to determine if asthma is well controlled
- Provides a snapshot of how well control has been over the last 4 weeks
- Helps provider know if symptoms go unreported
- Recognized by the NIH
- If possible, allow the child to answer the questions as much as possible

Enter Name				Today's Date:			
Enter Address				Patier	nt's Name:		
Enter City/State/Zip							
Childhood	Asthma	Control Te	st for chil	dren 4	to 11 yea	rs.	
This test will provide a so					-		
How to take the C			a criada darinia rediri	are profit to vicino	ng or a mangar be made	o a craige.	
Step 1 Let your child re			If your child needs he	elp reading or u	nderstanding the questi	on, you may	
help, but let you	ur child select the re	esponse. Complete the	remaining three ques				
		wers. There are no right		_	If your child's score is	10 or loss it	
Step 2 Write the number			ed.	19	may be a sign tha		
Step 3 Add up each so				or les	asthma is not cont	rolled as well	
Step 4 Take the test to t	the doctor to talk at	bout your child's total sci	ore.		as it could be. Bring the doctor to talk about		
Have your child o	omplete these	e questions.			the doctor to talk abou	at the results.	
L. How is your asthma today?							
4		400	500		Æ.	SCORE	
		1828					
•					-		
Very had		Rad	Food		Very good		
2. How much of a problem is:	unur arthma when you	run exercise or play sports?	-		11.7 g.1.5	_	
AS.	your Editing Wilet you	And puly sports	- 400		.60	$\overline{}$	
(A)							
		1000	101	· I	150		
			9		M		
9		0	0		9		
's a big problem, I can't do		O s a problem and I don't like	it. It's a little problem	but it's okay.	3 It's not a problem.		
's a big problem, I can't do		O a problem and I don't like	it. It's a little problem	but it's okay.	O It's not a problem.		
		o a problem and I don't like	it. It's a little problem	but it's okay.	it's not a problem.		
		a problem and I don't like	it. It's a little problem	but it's okay.	it's not a problem.		
3. Do you cough because of you	our asthma?		0	,	()		
). Do you cough because of your cough because of your cough because of your cough to you will be	our asthma?	Yes, most of the time.	it. It's a little problem	,	it's not a problem. No, none of the time		
3. Do you cough because of you	our asthma?	Yes, most of the time.	0	,	()		
). Do you cough because of your cough because of your cough because of your cough to you will be	our asthma?	Yes, most of the time.	0	,	()		
). Do you cough because of your cough because of your cough because of your cough to you will be	our asthma?	Yes, most of the time.	0	,	()		
). Do you cough because of your cough because of your cough because of your cough to you will be	our asthma?	Yes, most of the time.	0	,	()		
). Do you cough because of your cough because of your cough because of your cough to you will be	e. night because of your	Yes, most of the time.	0	the time.	()		
Yes, all of the time	e. night because of your	Yes, most of the time. asthma? Yes, most of the time.	Yes, some of Yes, some of the Yes, some	the time.	No, none of the time		
Yes, all of the time Yes, all of the time Yes, all of the time	e. night because of your :	Yes, most of the time. asthma? Yes, most of the time. questions on your	Yes, some of to Yes, some of the Yes, some	the time.	No, none of the time		
Yes, all of the time Yes, all of the time Yes, all of the time Up to the time Yes, all of the time Yes, all of the time Yes, all of the time	e. night because of your : he following of how many days did	Yes, most of the time. asthma? Yes, most of the time. Questions on your your child have any dayting	Yes, some of the company of the comp	the time.	No, nane of the time		
Yes, all of the time Source to the time The time time to the time to	e. night because of your :	Yes, most of the time. asthma? Yes, most of the time. Yes, most of the time. questions on your your child have any daytin	Yes, some of to the asthma symptoms?	the time.	No, none of the time No, none of the time		
Yes, all of the time Please complete to S. During the last 4 weeks.	e. night because of your : the following of how many days did 1-3 days	Yes, most of the time. asthma? Yes, most of the time. Questions on your your child have any dayting 4-10 days	Yes, some of the company of the comp	the time.	No, nane of the time		
Yes, all of the time Source to the time The time time to the time to	e. night because of your : the following of how many days did 1-3 days	Yes, most of the time. asthma? Yes, most of the time. Questions on your your child have any dayting 4-10 days	Yes, some of the company of the comp	the time.	No, none of the time No, none of the time		
Yes, all of the time Please complete to S. During the last 4 weeks.	e. night because of your : the following of how many days did 1-3 days	Yes, most of the time. asthma? Yes, most of the time. Questions on your your child have any dayting 4-10 days	Yes, some of the company of the comp	the time.	No, none of the time No, none of the time		
Yes, all of the time Somplete to the time The time to the	e. night because of your : the following of how many days did 1-3 days	Yes, most of the time. asthma? Yes, most of the time. Questions on your your child have any dayting 4-10 days	Yes, some of the company of the comp	the time.	No, none of the time No, none of the time		
Yes, all of the time Decrease complete for the time Soluting the last 4 weeks. Soluting the last 4 weeks. Soluting the last 4 weeks.	e. night because of your and the following of the how many days did the how many days days days days days days days day	Yes, most of the time. asthma? Yes, most of the time. questions on your your child have any daytin 3 4-10 days your child wheeze during to a state of the time.	Yes, some of Yes,	the time. 19-24 days 19-24 days	No, none of the time No, none of the time No, none of the time Everyday		
Yes, all of the time Please complete to the time During the last 4 weeks.	e. night because of your and the following of the how many days did the how many days days days days days days days day	Yes, most of the time. asthma? Yes, most of the time. questions on your your child have any daytin 3 4-10 days your child wheeze during to a state of the time.	Yes, some of Yes,	the time. 19-24 days 19-24 days	No, none of the time No, none of the time No, none of the time Everyday		
Yes, all of the time Decrease complete for the time Soluting the last 4 weeks. Soluting the last 4 weeks. Soluting the last 4 weeks.	e. night because of your and the following of the how many days did the how many days days days days days days days day	Yes, most of the time. asthma? Yes, most of the time. questions on your your child have any daytin 3 4-10 days your child wheeze during to a state of the time.	Yes, some of Yes,	the time. 19-24 days 19-24 days	No, none of the time No, none of the time No, none of the time Everyday		



Asthma Control Test (ACT)

Score of 19 or less, asthma may not be as in control as it could be

Higher the score = better control

1 =all the time -5 =not at all

Scores can range from 5 (1 for each answer) to 25 (5 for each answer)

FOR PATIENTS:

Take the Asthma Control Test™ (ACT) for people 12 yrs and older.

Know your score. Share your results with your doctor.

Write the number of each answer in the score box provided.

Please give this test to the study coordinator.

All of the time	1	Most of the time	2	Some of the time	3	A little of the time	0	None of the time	6	
2. During the p	ast 4 w	eeks, how ofter	have yo	ou had shortnes	s of brea	ith?				
More than once a day	1	Once a day	2	3 to 0 times a week	3	Once or twice a week	4	Not at all	6	
				asthma symplo rijer than usual i		ezing, coughing ming?	, shortne	ess of breath,	chest	
4 or more nights a week	1	2 or 3 nights a week	2	Once a week	3	Once or twice	0	Not at all	6	
4. During the p	ast 4 w	oeks, how often	have yo	ou used your res	scue inha	aler or nebulizer	medica	tion (such as	albuterol)?	
3 or more times per day	1	1 or 2 times per day	2	2 or 3 times per week	3	Once a week or less	0	Not at all	6	
5. How would y	you rate	your asthma o	ontrol du	uring the past 4	weeks?					
Not controlled at all	1	Poorty controlled	2	Somewhat controlled	3	Well controlled	0	Completely controlled	6	
										TOTA



Asthma Control Test Scoring = 25 is maximum score. High Is Good.

Score 15 or lower

Very poorly controlled

Score 19 or lower

- Not well controlled
- There is a 70-84% chance that this patient's asthma is not under control

Score 20 or more


- Well controlled
- 3 out of 4 patients are under control



Test for Respiratory and Asthma Control in Kids

TRACK—for children 0-4 years of age:

- 1. Validated
- 2. Includes risk
- 3. Easy to administer, caregiver completed
- Control status correctly classified in 78-81% of cases
- 5. Score of 80 or more means breathing problems under control
- 6. 5 questions total 3 last four weeks1 last three months1 last 12 months





Questions





Our Vision

A World Free of Lung Disease



